Kineta, Inc. (KANT) - Total Assets
Based on the latest financial reports, Kineta, Inc. (KANT) holds total assets worth $1.40 Million USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Kineta, Inc. to assess the company's total reinvestment commitment from operating cash flow.
Kineta, Inc. - Total Assets Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Kineta, Inc. to evaluate the quality of earnings relative to operating cash generation.
Kineta, Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Kineta, Inc.'s total assets of $1.40 Million consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.83 Million | 37.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KANT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kineta, Inc.'s current assets represent 58.1% of total assets in 2023, a decrease from 80.6% in 2020.
- Cash Position: Cash and equivalents constituted 56.3% of total assets in 2023, down from 80.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 37.3% of total assets.
Kineta, Inc. Competitors by Total Assets
Key competitors of Kineta, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩280.93 Billion |
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
|
USA | $497.60 Million |
|
Ascletis Pharma Inc
F:2VJ
|
Germany | €2.07 Billion |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Kineta, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.14 | 1.39 | 1.39 |
| Quick Ratio | 0.14 | 1.39 | 1.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.05 Million | $3.65 Million | $3.65 Million |
Kineta, Inc. - Advanced Valuation Insights
This section examines the relationship between Kineta, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.65 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | -41.0% |
| Total Assets | $10.28 Million |
| Market Capitalization | $4.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kineta, Inc.'s assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kineta, Inc.'s assets decreased by 41.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kineta, Inc. (2020–2023)
The table below shows the annual total assets of Kineta, Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $10.28 Million | -41.03% |
| 2022-12-31 | $17.43 Million | +30.57% |
| 2021-12-31 | $13.35 Million | -6.64% |
| 2020-12-31 | $14.30 Million | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more